Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery

Colorectal Neoplasms Clinical Trial

Official title:

Clinical Study of the Impact of Hyperthermic Intraperitoneal Chemotherapy on Peritoneal Recurrence and Prognosis of Patients With Stage T4 Colorectal Cancer After Radical Surgery: A Multicentre Randomised Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03221608
• Other study ID #: zs6yhmjHIPEC2017
• Status: Not yet recruiting
• Phase: Phase 3
• First received: July 17, 2017
• Last updated: July 17, 2017
• Start date: August 1, 2017
• Est. completion date: August 1, 2024

Study information

• Verified date: July 2017
• Source: Sixth Affiliated Hospital, Sun Yat-sen University
• Contact: MeiJin Huang, MD
• Phone: 86-020-38250745
• Email: meijinhuang3[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This multicentric study aims to determine if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to prevent the development of peritoneal carcinomatosis in addition to the standard adjuvant systemic treatment after surgery.

Description:

Background:

Colorectal cancer (CRC) is the third most common malignancy worldwide, nearly 1.4 million new cases every year, for about 694000 deaths. Surgery is the primary treatment and results in a cure rate of approximately 50% of the patients. However, recurrence following surgery is a major problem, the second most common site of recurrence was peritoneum, which was as a result of the intraperitioneal free cancer cells (FCC) and microscopic cancer (MC). The remaining free cancers and microscopic cancer in abdominal cavity can not be killed completely because of the "peritoneal-plasma barrier" and "non-sufficient drug concentration in abdominal cavity by systemic venous chemotherapy". In recent years, hyperthermic intraperitioneal chemotherapy(HIPEC) has already been shown to be effective in improving the 5 year survival rate of colorectal cancer. However, lots of clinically studies for patients with colorectal cancer are advanced, it is not sure yet whether surgery combined with HIPEC is effective on decreasing the rate of peritoneal carcinomatosis in T4 stage colorectal cancer. The efficacy tend to be magnified when stage T4 patients account for less, confusing HIPEC for treatment of patients with advanced colorectal cancer. Therefore, the aim of this study is to investigate the clinical efficacy of HIPEC in T4 stage patients, ruling out the effects of different T stages on curative effect. The results of this study will hopefully provide the clinical basis for improving the prognosis of patients with advanced colorectal cancer.

Study design： This is a multicenter study in which 300 patients with T4 colorectal cancer will be randomized to surveillance alone (control group) or HIPEC (experimental group) after resection of the primary tumor, either by laparoscopy or open approach. Subsequently, all patients started mfolfox6 chemotherapy after operation in a month. Adverse reaction of chemotherapy during chemotherapy and post chemotherapy period will be recorded.

Study population:

The patients with colorectal cancer (T4N0-2M0) will undergo a curative resection by laparoscopy or open approach.

Intervention:

HIPEC equipment used in the perfusion fluid (Lobaplatin of 50mg completely dissolved in 3000ml saline solution) is headed to 43℃. Then, it is injected into the peritoneal cavity by flow velocity of 200-400ml/min for 60 minutes.

Outcomes:

Primary endpoint is incidence of endoperitoneal recurrence at 36 months. Secondary endpoints are disease-free survival, overall survival, incidence of peritoneal carcinomatosis at end of follow-up with or without concomitant liver/lung metastases, quality of life and morbidity rate.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: August 1, 2024
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Histologically-proven colorectal adenocarcinoma

2. Patients with colon cancer or intraperitoneal rectal cancer with clinical (by CT) T4 tumors, any N, M0

3. Signed informed consent

4. White blood cell count of at least 3000/mm3, platelet count of at least 100.000/mm3

5. No bleeding diathesis or coagulopathy

6. Patients without chemotherapy, radiation or other anti-cancer treatment before the clinical trial

Exclusion Criteria:

1. Liver and/or lung metastases

2. Pregnant women or likely to be pregnant

3. Severe hepatic and / or renal dysfunction

4. Impossibility of an adequate follow-up

5. Without history of cancer during last 5 years

6. Other concurrent chemotherapy

7. Severe or uncontrolled mental illness

8. Patients with epilepsy required to be treated

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Procedure:
• Surgery and HIPEC with Lobaplatin
The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
• Surgery without HIPEC
The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.

Locations

Country	Name	City	State
n/a

Sponsors (11)

Lead Sponsor

Collaborator

Sixth Affiliated Hospital, Sun Yat-sen University

Affiliated Tumor Hospital of Guangzhou Medical University, First Affiliated Hospital of Jinan University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou General Hospital of Guangzhou Military Command, Nanfang Hospital of Southern Medical University, Second Affiliated Hospital of Guangzhou Medical University, Second Affiliated Hospital, Sun Yat-Sen University, Tcm-integrated Cancer Center of Southern Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Zhujiang Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of endoperitoneal recurrence at 36 months		36 months
Secondary	Disease-free survival (DFS)		3 years
Secondary	Disease-free survival (DFS)		5 years
Secondary	Overall survival (OS)		3 years
Secondary	Overall survival (OS)		5 years
Secondary	Quality of life	To evaluate quality of life with EORTC QLQ-30 questionnaire	3 years
Secondary	HIPEC toxicity rate		1 month
Secondary	HIPEC toxicity rate		6 month